Cike Peng


+49 6221 56 8403


Im Neuenheimer Feld 440




Breast cancer is the most common malignant disease in women of western countries. Metastases of breast cancer at distant sites are the main cause of death. Although a number of biological markers have been investigated to estimate the outcome of patients, the sufficient marker for the prognosis of metastatic breast cancer is still limited. On the other hand, as a complex and heterogeneous disease, the metastatic tumor of each individual has variant response to the treatment. To improve the survival of metastatic breast cancer patients, selection of sufficient treatment is primarily based on the determination of the treatment effectiveness by monitoring the patients’ response. Hyaluronic acid is a major macropolysaccharide in extracellular matrix. It has been experimentally evidenced to be involved in cancer. The production of hyaluronic acid has been shown to enhance cell proliferation and angiogenesis. Poorly differentiated adenocarcinomas with high stromal hyaluronic acid content tended to have enhanced invasiveness and grew aggressively. Interaction between hyaluronic acid and its receptor on tumor cell surface, CD44, has also been related to tumor cell dissemination, the first step of cancer metastases. The aim of this study is to investigate the relationship between tumor progression and plasma hyaluronic acid level and to evaluate its prognostic potential. Further, we also aim to estimate the potential of hyaluronic acid as a treatment monitoring marker of metastatic breast cancer

to top
powered by webEdition CMS